Priya Prahalad, MD, PHD
Pediatric Endocrinology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Prahalad’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A120955 · Current
Licensed to practise in California · since 2012 · expires 2028-04-30 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Endocrinology
- American Board of Pediatrics - Pediatrics
- American Board of Preventive Medicine - Clinical Informatics
Medicaid work
$11,465 in 2024
Medicaid paid $11,465 for 115 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 57 | $9,201 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 45 | $1,723 |
| Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 13 | $541 |
| 2024 | 115 | 3 | 16 | $11,465 |
| 2023 | 173 | 3 | 24 | $10,709 |
| 2022 | 189 | 3 | 20 | $14,604 |
| 2021 | 247 | 3 | 26 | $28,486 |
| 2020 | 192 | 2 | 24 | $20,987 |
| 2019 | 249 | 2 | 34 | $28,750 |
| 2018 | 195 | 2 | 25 | $17,819 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 72 | $6,801 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 67 | $2,520 |
| Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 34 | $1,388 |
2022
| Return visit (30+ min) | 84 | $8,135 |
| Long return visit (40+ min) | 27 | $3,711 |
| Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 78 | $2,758 |
2021
| Long return visit (40+ min) | 174 | $25,176 |
| Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 59 | $2,035 |
| Return visit (30+ min) | 14 | $1,276 |
2020
| Long return visit (40+ min) | 108 | $13,198 |
| Return visit (30+ min) | 84 | $7,788 |
2019
| Long return visit (40+ min) | 209 | $25,384 |
| Return visit (30+ min) | 40 | $3,366 |
2018
| Return visit (30+ min) | 134 | $10,482 |
| Long return visit (40+ min) | 61 | $7,337 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 12 Part D prescriptions in 2018. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2018 | 12 | None | 0% (0) | None | $6,179 |
| 2017 | 18 | None | 0% (0) | 78% | $7,188 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$8,399 in 2025
| 2025 | 4 | 11 | $6,643 | $8,399 |
| 2024 | 2 | 9 | $7,425 | $8,881 |
| 2023 | 1 | 1 | None | $64 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Tzield | $4,475 | 3 payments
|
| Sanofi-Aventis U.S. | Tzield | $2,555 | 1 payment
|
| Insulet | Omnipod | $1,320 | 6 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $49 | 1 payment
|
See all 11 published payments
| Insulet | Meals · 2025-12-13 | Omnipod | $54 |
| Insulet | Meals · 2025-12-13 | Omnipod | $60 |
| Insulet | Travel · 2025-12-12 | Omnipod | $496 |
| Insulet | Travel · 2025-12-12 | Omnipod | $246 |
| Insulet | Travel · 2025-12-12 | Omnipod | $359 |
| Insulet | Meals · 2025-12-12 | Omnipod | $106 |
| Genzyme | Meals · 2025-06-19 | Tzield | $165 |
| Genzyme | Consulting · 2025-06-19 | Tzield | $4,088 |
| Genzyme | Travel · 2025-06-19 | Tzield | $222 |
| Abbott Laboratories | Meals · 2025-04-09 | Freestyle Libre 3 | $49 |
| Sanofi-Aventis U.S. | Consulting · 2025-03-18 | Tzield | $2,555 |
See earlier years (2024, 2023)
2024: $8,881
| Sanofi-Aventis U.S. | Tzield | $8,683 | 8 payments
|
| Insulet | Omnipod | $198 | 1 payment
|
2023: $64
| MannKind | Afrezza | $64 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Dexcom, Inc. · Multi-Session Evaluation of the Investigational Dexcom Continuous Glucose Monitoring (Cgm) Sensor in Adult and Pediatric Participants · 2025 | Their institution | $5,268 |
Professional record
- NPI
- 1285950949
- Licence
- CA A120955California A120955: Current · expires 2028-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0205X (2080P0205X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2010-04-20
- NPI last updated
- 2016-01-13
This is when the NPI record was last certified, not a medical board exam.